Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CIL001
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase I
Sponsor : Shionogi
Deal Size : $16.0 million
Deal Type : Agreement
Japan's Shionogi Inks €400 M Deal with French Firm Cilcare
Details : Through the agreement with Cilcare to acquire the exclusive license to develop, manufacture, and commercialize CIL001 for the treatment of patients with hearing loss.
Brand Name : CIL001
Molecule Type : Small molecule
Upfront Cash : $16.0 million
June 10, 2024
Lead Product(s) : CIL001
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase I
Sponsor : Shionogi
Deal Size : $16.0 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?